Results 111 to 120 of about 110,187 (167)

Hormone Replacement Therapy Uptake and Discontinuation Trends From 1996‐2023: An Observational Study of the Welsh Population

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To analyse prescribing trends for oral and transdermal hormone replacement therapy (HRT) in Wales from 1996 to 2023, including predictors of discontinuation within one year of initiation. Design Observational study using the Secure Anonymised Information Linkage (SAIL) databank.
Robin Andrews, Arron Lacey, Kate Bache, Emma J. Kidd   +3 more
wiley   +1 more source

Research progress of antibody-drug conjugates in the treatment of endometrial cancer. [PDF]

Front Oncol
Jiang Y, Yao Q.
europepmc   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Women's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue. Objectives To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them. Search Strategy Embase, MEDLINE,
Sarah Bunnewell, Sabrina Keating, Jo Parsons, Martha Hickey, Sarah Hillman   +4 more
wiley   +1 more source

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer. [PDF]

Clin Cancer Res
Rubinstein MM, Ge JY, Zhou Q, Iasonos A, Weigelt B, Selenica P, Muldoon DM, Bandlamudi C, Kaczynski C, Paroder V, Higgins K, Shah P, Weissblum S, Lyn A, Liu YL, Bose S, Cohen SM, Green AK, Grisham RN, Kyi C, O'Cearbhaill RE, Tew WP, Berger MF, Aghajanian C, Makker V.   +24 more
europepmc   +1 more source

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Primary Yolk Sac Tumor of the Endometrium: A Case Report and Comprehensive Literature Review. [PDF]

Case Rep Pathol
Cheng H, Song Y, Shi SS.
europepmc   +1 more source

Reproductive Challenges of the Ageing Female: A Comprehensive Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Changes in societal norms over the last few decades have resulted in novel family planning trends, notably delayed childbearing and increased maternal age at the birth of the first child. Despite advances in reproductive medicine, ageing poses significant challenges.
Sofia Bitzika, Meletios P. Nigdelis, Angelos Daniilidis, Erich‐Franz Solomayer, Irene Lambrinoudaki, Efstratios M. Kolibianakis, Dimitrios G. Goulis   +6 more
wiley   +1 more source

Three-dimensional reconstruction technology facilitates surgical planning for endometrial cancer with pelvic ectopic kidney: a case report. [PDF]

Gynecol Oncol Rep
Li Y, Mi J, Wang P, Zhang K, Yan L, Deng Y, Li M.   +6 more
europepmc   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source